TriangleThe film gives the main points. The full list below is copied from the registry; the study team makes the final decision.
- Age18 Years to 120 Years
- SexFemale
- Healthy volunteersNo
You may be able to join if
- Untreated, pathologically or cytologically-confirmed diagnosis of FIGO Stage IB3, II, or IIIA-IIIC1 bulky ( ≥ 6cm) or Stage IVA or Stage IVB (FIGO 2018) squamous, adenosquamous, or adenocarcinoma of the uterine cervix with limited metastatic burden (not requiring urgent systemic therapy).
- Adequate organ and marrow function
- Gynecologic Oncology Group performance status of 0, 1, or 2
- Patient agrees to use two forms of birth control if they are of child-bearing potential
- Ability to understand and the willingness to sign a written informed consent document
You cannot join if
- Presence of another concurrent active invasive malignancy
- Prior invasive malignancy diagnosed within the last three years, with the following two exceptions: [a] non-melanoma skin cancer and/or [b] prior in situ carcinoma of the cervix
- Receipt of prior pelvic radiotherapy for any reason that would contribute radiation dose that would exceed tolerance of normal tissues, at the discretion of the treating physician
- Currently receiving any other investigational agent(s) for the treatment of cancer
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to Cisplatin or other agents used in study
- Presence of uncontrolled intercurrent illness as determined by the treating physician
- pregnant or lactating
- Patients with a known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better